Profile data is unavailable for this security.
About the company
Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST, EpiSwitch PSE, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
- Revenue in GBP (TTM)617.00k
- Net income in GBP-11.11m
- Incorporated2007
- Employees45.00
- LocationOxford Biodynamics PLC26 Beaumont StreetOXFORD OX4 2WBUnited KingdomGBR
- Phone+44 186 551 8910
- Fax+44 186 551 1418
- Websitehttps://www.oxfordbiodynamics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRISM' Therapeutics Corp | 0.00 | -349.70k | 3.10m | 4.00 | -- | 1.50 | -- | -- | -0.0408 | -0.0408 | 0.00 | 0.0634 | 0.00 | -- | -- | 0.00 | -8.18 | -8.91 | -12.38 | -9.27 | -- | -- | -- | -- | -- | -1.01 | 0.00 | -- | -- | -- | 9.04 | -- | -- | -- |
| BSF Enterprise PLC | 67.24k | -1.71m | 3.88m | 4.00 | -- | 0.9702 | -- | 57.63 | -0.0166 | -0.0166 | 0.0007 | 0.0387 | 0.0128 | 1.79 | 0.0425 | 16,810.00 | -32.47 | -- | -34.78 | -- | -44.74 | -- | -2,542.56 | -- | 6.17 | -218.85 | 0.0287 | -- | -- | -- | -61.40 | -- | -- | -- |
| Oxford Biodynamics PLC | 617.00k | -11.11m | 4.25m | 45.00 | -- | 1.69 | -- | 6.89 | -0.0643 | -0.0643 | 0.0035 | 0.008 | 0.0487 | 1.20 | 0.379 | 13,711.11 | -87.64 | -39.72 | -114.28 | -45.52 | 41.49 | -- | -1,800.32 | -1,324.62 | 0.6156 | -87.72 | 0.7873 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
| Kanabo Group PLC | 1.14m | -8.18m | 6.70m | 17.00 | -- | 1.13 | -- | 5.88 | -0.013 | -0.013 | 0.0018 | 0.0094 | 0.1054 | 16.28 | 43.85 | 67,058.82 | -75.70 | -75.83 | -81.16 | -83.33 | 7.89 | -- | -718.33 | -1,267.35 | 2.72 | -63.43 | 0.0337 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
| Oncimmune Holdings PLC | 1.21m | -3.14m | 12.42m | 33.00 | -- | -- | -- | 10.23 | -0.0423 | 0.0958 | 0.0164 | -0.0172 | 0.1756 | 1.19 | 0.6917 | 36,787.88 | -45.43 | -- | -- | -- | 63.34 | -- | -258.65 | -- | 1.01 | -0.6511 | 1.32 | -- | -- | -- | -- | -- | -- | -- |
| Celadon Pharmaceuticals PLC | 130.00k | -5.23m | 18.24m | -- | -- | 7.20 | -- | 140.34 | -0.0827 | -0.0827 | 0.002 | 0.0368 | 0.0145 | 26.79 | 0.1194 | -- | -58.39 | -- | -67.06 | -- | -3,433.85 | -- | -4,024.62 | -- | 1.56 | -8.76 | 0.6608 | -- | 212.50 | -- | 58.01 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Vulpes Investment Management Pte Ltd.as of 08 Apr 2024 | 29.65m | 9.51% |
| Arbuthnot Latham & Co. Ltd.as of 01 Oct 2024 | 26.24m | 8.41% |
| Unicorn Asset Management Ltd.as of 08 Apr 2024 | 25.13m | 8.06% |
| Janus Henderson Investors UK Ltd.as of 01 Oct 2024 | 16.17m | 5.18% |
| Lombard Odier Asset Management (Europe) Ltd.as of 14 Oct 2024 | 15.57m | 4.99% |
| Cantor Fitzgerald Europeas of 05 Apr 2024 | 8.02m | 2.57% |
| Investec Wealth & Investment Ltd.as of 15 Jan 2024 | 7.32m | 2.35% |
| Chelverton Asset Management Ltd.as of 01 Oct 2024 | 6.99m | 2.24% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Oct 2024 | 5.62m | 1.80% |
| Armistice Capital LLCas of 04 Feb 2022 | 4.93m | 1.58% |
